Evaxion Biotech's lung cancer candidate ready for clinic
The next candidate developed by Evaxion Biotech is ready to enter the clinical phase. This candidate is a potential treatment for non-small cell lung cancer called EVX-03, the biotech firm reveals.
by christopher due karlsson, translated by catherine brett
Biotech firm Evaxion Biotech has decided to take its EVX-03 candidate, a potential treatment for non-small cell lung cancer (NSCLC), into the clinical phase.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
